October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Publication|Articles|April 23, 2026
Pharmacy Practice in Focus: Oncology
- April 2026
- Volume 8
- Issue 3
Navigating Interdisciplinary Care for Tumor-Infiltrating Lymphocyte Therapy in Melanoma
Author(s)Rebekah R. Dyer, PharmD, BCPS
Fact checked by: Kirsty Mackay
Lifileucel treats advanced melanoma by harvesting, expanding, and reinfusing a patient's own tumor-infiltrating immune cells.
Advertisement
Advertisement
Tumor-infiltrating lymphocyte (TIL) immunotherapy is a cellular treatment that utilizes a patient’s immune cells to fight and kill cancer cells. Approved by the FDA in 2024, lifileucel (Amtagvi; Iovance Biotherapeutics, Inc) is the first autologous cellular therapy approved for a cancerous solid tumor, specifically in adult patients with unresectable or metastatic melanoma.
Related to this article
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
A cohort study linked higher BMI and abdominal obesity to increased cancer risk in young adults, reinforcing the importance of early weight management.
Study shows prior authorization and high out-of-pocket costs drive prescription abandonment, limiting Medicare Part D blood cancer treatment access to oral anticancer medications.
Advertisement
Advertisement